Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor. In this report, we show that modulation of s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Grohar, Patrick J, Griffin, Laurie B, Yeung, Choh, Chen, Qing-Rong, Pommier, Yves, Khanna, Chand, Khan, Javed, Helman, Lee J
Formato: Artigo
Lenguaje:Inglês
Publicado: Neoplasia Press Inc. 2011
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033593/
https://ncbi.nlm.nih.gov/pubmed/21403840
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares